High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle- stimulating hormone, and testosterone in normal men

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 5, 1997, Pages 1403-1408

  Behre, Hermann M ^a   Kliesch, Sabine ^a   Pühse, Gerald ^a   Reissmann, Thomas ^b   Nieschlag, Eberhard ^a  

^a INST OF REPRO MED OF THE UNIV   (Germany)

^b ASTA MEDICA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; ESTRADIOL; FOLLITROPIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PLACEBO; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG MECHANISM; ERYTHEMA; FLUOROIMMUNOASSAY; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN RELEASE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL;

EID: 0030906899     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.5.1403     Document Type: Article

References (18)

1. Filicori M, Flamigni C, eds. 1996 Treatment with GnRH analogs: controversies and perspectives. New York, London: Parthenon.
2. Behre HM, Nashan D, Hubert W, Nieschlag E. 1992 Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab. 74:84-90.
3. Pavlou SN, Brewer K, Farley MG, et al. 1991 Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab. 73:1360-1369.
4. Tom L, Bhasin S, Salameh W, et al. 1992 Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab. 75:476-483.
5. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ. 1993 Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab. 77:427-432.
6. Behre HM, Klein B, Steinmeyer E, McGregor GP, Voigt K, Nieschlag E. 1992 Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab. 75:393-398.
7. Reissmann T, Engel J, Hilgard P, et al. 1996 LHRH antagonist cetrorelix (INN): biological and clinical characteristics. In: Filicori M, Flamigni C, eds. Treatment with GnRH analogs: controversies and perspectives. New York, London: Parthenon; 81-87.
8. Bajusz S, Csernus VJ, Janaky S, Bokser L, Fekete M, Schally AV. 1988 New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Peptide Protein Res. 32:425-435.
9. Behre HM, Böckers A, Schlingheider A, Nieschlag E. 1994 Sustained suppression of serum LH, FSH, and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin Endocrinol (Oxf). 40:241-248.
10. Conn PM, Janovick JA, Stanislaus D, Kuphal D, Jennes L. 1995 Molecular and cellular bases of gonadotropin-releasing hormone action in the pituitary and central nervous system. Vitam Horm. 50:151-214.
11. Padmanabhan V, Evans NP, Dahl GE, McFadden KL, Mauger DT, Karsch FJ. 1995 Evidence for short or ultrashort loop negative feedback of gonadotropin-releasing hormone secretion. Neuroendocrinology. 62:248-258.
12. Weinbauer GF, Hankel P, Nieschlag E. 1992 Exogenous gonadotrophin-releasing hormone (GnRH) stimulates LH secretion in male monkeys (Macaca fascicularis) treated chronically with high doses of a GnRH-antagonist. J Endocrinol. 133:439-445.
13. Katt JA, Duncan JA, Herbon L, Barkan A, Marshall JC. 1985 The frequency of gonadotropin-releasing hormone stimulation determines the number of pituitary gonadotropin-releasing hormone receptors. Endocrinology. 116:2113-2115.
14. Pinski J, Lamharzi N, Halmos G, et al. 1996 Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology. 137:3430-3436.
15. Halmos G, Schally AV, Pinski J, Vandillo-Buenfil M, Groot K. 1996 Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist cetrorelix. Proc Natl Acad Sci USA. 93:2398-2402.
16. Behre HM, Kliesch S, Lemcke B, Nieschlag E. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by 19-nortestosterone alone in normal men. Proc of the 77th Annual Meet of the Endocrine Soc. 1995; OR29-6.
17. Engel J, Reissmann T, Klenner T, et al. 1996 Sustained release formulations for long-term LHRH antagonist administration. In: Filicori M, Flamigni C, eds. Treatment with GnRH analogs: controversies and perspectives. New York, London: Parthenon; 69-74.
18. Behre HM, Kliesch S, Bock W, et al. 1995 Suppression of serum testosterone in normal men by cetrorelix pamoate, a GnRH antagonist depot preparation. Exp Clin Endocrinol Diabetes. 103(Suppl 1):141.